The results of the Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER; number. Editorial from The New England Journal of Medicine — JUPITER Clinical Directions — Polling Results. Authors & Reviewers · Submit a Manuscript · Subscribers · Institutions · Media · Advertisers · Agents · Permissions · Reprints · NEJM Career.

Author: Mooguktilar Zulugore
Country: Nicaragua
Language: English (Spanish)
Genre: History
Published (Last): 20 September 2010
Pages: 240
PDF File Size: 2.56 Mb
ePub File Size: 16.60 Mb
ISBN: 347-7-88856-756-3
Downloads: 10118
Price: Free* [*Free Regsitration Required]
Uploader: Mosida

The rosuvastatin group did not have a significant increase in myopathy or cancer but did have a higher incidence of physician-reported diabetes.

The rates of the primary end point were 0. Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, we hypothesized that people with elevated high-sensitivity C-reactive protein levels but without hyperlipidemia might benefit from statin treatment. Retrieved from ” https: Results, Controversies, and Implications for Prevention”. There were no significant differences between the treatment groups with respect to muscle pain, muscle weakness, hepatic function, or renal function; however, the researchers noted small but statistically significant increases in the rate of physician-reported diabetes and glycated hemoglobin values in the rosuvastatin group, an effect that has also been seen in studies with other statins.

Cleve Clin J Med. The article’s authors critiqued what they saw as flaws in the trial, pointing out that the cardiovascular mortality rate and the case-fatality rate for myocardial infarction were much lower than they expected. From Wikipedia, the free encyclopedia.


The trial was stopped after a median follow-up of 1. The trial focused on patients with normal low-density lipoprotein LDL cholesterol levels but increased levels of high-sensitivity C-reactive protein hs-CRP. The trial was stopped early, after just 1.

They also raised concerns about conflict of interest in the trial design and leadership: Am J Kidney Dis. The trial was sponsored by AstraZenecathe marketer of Crestor rosuvastatin.

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

This page was last edited on 4 Novemberat The trial analyzed 17, patients without evidence of heart disease but with high CRP levels. Inresults presented at the American Heart Association meeting and published in the New England Journal of Medicine found that patients with low-to-normal LDL cholesterol receiving rosuvastatin had a lower rate of major cardiovascular events. On the role of C-reactive protein, a study employing Mendelian randomizationpublished in the Journal of the American Medical Association suggested that CRP does not play a causal role in cardiovascular disease; the results may argue against CRP’s use as a marker of cardiovascular disease risk or for identifying subjects for statin therapy as in JUPITER, and more strongly argue against using CRP as a therapeutic target per se.

In this trial of apparently healthy persons without hyperlipidemia but jypiter elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events. Views Read Edit View history. Because half of all vascular events occur in patients with normal or low levels of LDL cholesterol, Jupier was designed to determine whether hs-CRP testing could identify these patients, and whether statin therapy could prevent cardiovascular events among them.


Retrieved July 1, Clinical trials related to cardiology Clinical trials sponsored by AstraZeneca Statins. Compared to patients taking a placebopatients given rosuvastatin had reductions in LDL and CRP levels, and a reduction of 0.

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Consistent effects were observed in all subgroups evaluated. N Engl J Med. By using this site, you agree to the Terms of Use and Privacy Policy. Michel de Lorgeril, et al. JUPITER was a randomized double-blind placebo-controlled jupiiter investigating the use of rosuvastatin in the primary prevention of cardiovascular disease.

We randomly assigned 17, apparently healthy men and women with low-density lipoprotein LDL cholesterol levels of less than mg per deciliter 3.

Cardiovascular Quality and Outcomes.


They concluded that, “The results of the trial do not support the use of statin treatment for primary prevention of cardiovascular diseases and raise troubling questions concerning the role of commercial sponsors. Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events.

An I ntervention T rial E valuating R osuvastatin trial was a clinical trial aimed at evaluating whether statins reduce heart attacks and strokes in people with normal cholesterol levels. Comment in Ann Intern Med.